Leerink Partners Keeps Their Buy Rating on uniQure (QURE)

Business Insider

2 days ago

Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on uniQure (QURE – Research Report) on June 3 and set a price target of $48.00. The company's shares closed yesterday at $14.96.
Confident Investing Starts Here:
Schwartz covers the Healthcare sector, focusing on stocks such as uniQure, KalVista Pharmaceuticals, and Sarepta Therapeutics. According to TipRanks, Schwartz has an average return of 10.5% and a 42.05% success rate on recommended stocks.
Currently, the analyst consensus on uniQure is a Strong Buy with an average price target of $38.40, implying a 156.68% upside from current levels. In a report released on June 3, H.C. Wainwright also reiterated a Buy rating on the stock with a $70.00 price target.
Based on uniQure's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.57 million and a GAAP net loss of $43.64 million. In comparison, last year the company earned a revenue of $8.49 million and had a GAAP net loss of $65.62 million
Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of QURE in relation to earlier this year. Most recently, in March 2025, Jeannette Potts, the CLO of QURE sold 7,076.00 shares for a total of $72,812.04.